PerspectivesProposal for a new clinical end point to evaluate the efficacy of drugs and devices in the treatment of chronic heart failure*
Section snippets
Evaluation of clinical status
Some investigators have proposed that the inconsistent results of intermediate-term trials can be explained by inherent limitations of the measures used to evaluate changes in clinical status. Several different measures have been used to evaluate the functional capacity of patients with heart failure including 1) the direct assessment of symptoms, 2) exercise tolerance, 3) New York Heart Association (NYHA) functional class, 4) global assessment of progress, and 5) quality-of-life assessments.
Analyzing the effects of drugs for heart failure
Some investigators have proposed that the inconsistent results of intermediate-term trials are caused by inherent limitations in the statistical approaches that have been used to analyze data. Two areas of specific concern have been identified: analysis of missing data and analysis of efficacy data collected after a major nonfatal clinical event.
Experience in clinical trials using a conventional approach
Until recently, intermediate-term clinical trials identified a single measure of efficacy (designated as the primary end point) and the results were evaluated using a completers analysis or the last-observation-carried-forward method, which failed to appropriately account for the occurrence of major clinical events or missing data. Consequently, these trials frequently produced results that proved to be inconsistent with the biological and clinical effects of the drug established in other
Development of a clinical composite score
These examples highlight the critical flaws in our current approach to conducting intermediate-term studies in the evaluation of new drugs for the treatment of chronic heart failure. Experience to date indicates that a strategy that minimizes the importance of major clinical events in analyzing the effects of treatment on a single clinical end point is inherently biased and carries an unacceptable risk of yielding results that do not reflect the true potential of the new treatment. Recognition
Conclusions
A new clinical composite score has been developed to assess the clinical efficacy of new drugs for heart failure. Retrospective analysis of earlier trials suggests that the use of the composite score would have avoided many of the misleading conclusions of these studies. The new clinical composite score has been and is being used prospectively in many recently completed and ongoing trials, including those evaluating the efficacy of endothelin antagonists, cytokine antagonists, vasopressin
References (12)
Current perspectives on the design of phase II trials of new drugs for the treatment of heart failure
Am Heart J
(2000)How should we judge the efficacy of drug therapy in patients with chronic congestive heart failure? The insights of six blind men
J Am Coll Cardiol
(1987)The placebo effect in heart failure
Am Heart J
(1990)- et al.
Spectrum and outcome of congestive heart failure in a hospitalized population
Am Heart J
(1993) - et al.
Meta-analysis of morbidity and mortality in five exercise capacity trials evaluating ramipril in chronic congestive cardiac failure
Am J Cardiol
(1996) - et al.
Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure
Lancet
(1997)
Cited by (357)
Electrical therapies in heart failure: Evolving technologies and indications
2024, Presse MedicaleCost-effective analysis of automated programming optimization in cardiac resynchronization therapy: Holistic Markov modelling
2022, Journal of CardiologyCitation Excerpt :The clinical model inputs are presented in Table 1. Clinical response of CRT was defined by using CCS, which was developed by Packer and has been used in multiple CRT trials [9, 10]. The probabilities of response (“Improved,” “Unchanged,” and “Worsened”) in both arms were derived from a propensity analysis by Singh et al. [11].
CRT Efficacy in “Mid-Range” QRS Duration Among Asians Contrasted to Non-Asians, and Influence of Height
2022, JACC: Clinical Electrophysiology
- *
Reprint requests: Milton Packer, MD, Division of Circulatory Physiology, College of Physicians and Surgeons, 630 W 168th St, Columbia University, New York, NY 10032.